This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jennemann, R. Articles by Wiegandt, H. Search for Related Content PubMed PubMed Citation Articles by Jennemann, R. Articles by Wiegandt, H.

Glycosphingolipids of Human Gliomas¹

Zentrum für Operative Medizin, Abtl. Neurochirurgie [R. J., A. R., B. L. B.], Zentrum für Pathologie, Abtl. Neuropathologie [H-D. M.], and Physiologisch-Chemisches Institut [H. W.], Philipps-Universitat Marburg, Federal Republic of Germany

Histologically characterized human gliomas of various grades of malignancy obtained during surgery were extracted, and their glycolipids were isolated and partially identified. Among the gliomas analyzed, three types of glycolipid component distribution could be identified. The glycosphingolipid (GSL) type I pattern correlated closely with that of the most malignant gliomas (Grade IV). Its neutral GSLs consisted of glucosyl- and, as a major component, dihexosylceramide, in addition to globo- and neolactotetraosylceramide. Galactosylceramide and sulfatide were absent. The gangliosides of GSL type I were almost exclusively of the G_Lac family, aside from small amounts of neolacto-series-derived species. The neutral components of GSL type II were similar to those of GSL type I. The acidic compounds of GSL type II were gangliosides of the G_tri family and trace amounts of neolacto-series sialoglycolipids, in addition to G_Lac1 and G_Lac2. GSL type II contained no G_tet gangliosides and no sulfatide. The GSL type III pattern was that of the most benign gliomas, with all glycolipids present that are found in normal brain and, in addition, those of the GSL type II.

¹ This work was generously supported by grants from the Ursula Kulemann-Stiftung and Deutsche Forschungsgemeinschaft (Wi222/27).

Received 11/14/89. Accepted 7/25/90.

This article has been cited by other articles:

				R. Jennemann, R. Sandhoff, L. Langbein, S. Kaden, U. Rothermel, H. Gallala, K. Sandhoff, H. Wiegandt, and H.-J. Grone Integrity and Barrier Function of the Epidermis Critically Depend on Glucosylceramide Synthesis J. Biol. Chem., February 2, 2007; 282(5): 3083 - 3094. [Abstract] [Full Text] [PDF]

				R. Jennemann, R. Sandhoff, S. Wang, E. Kiss, N. Gretz, C. Zuliani, A. Martin-Villalba, R. Jager, H. Schorle, M. Kenzelmann, et al. Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth PNAS, August 30, 2005; 102(35): 12459 - 12464. [Abstract] [Full Text] [PDF]

				R. Sandhoff, R. Geyer, R. Jennemann, C. Paret, E. Kiss, T. Yamashita, K. Gorgas, T. P. Sijmonsma, M. Iwamori, C. Finaz, et al. Novel Class of Glycosphingolipids Involved in Male Fertility J. Biol. Chem., July 22, 2005; 280(29): 27310 - 27318. [Abstract] [Full Text] [PDF]

				T. C. Comas, T. Tai, D. Kimmel, B. W. Scheithauer, P. C. Burger, D. K. Pearl, S. D. Jewell, and A. J. Yates Immunohistochemical staining for ganglioside GD1b as a diagnostic and prognostic marker for primary human brain tumors Neuro-oncol, October 1, 1999; 1(4): 261 - 267. [Abstract] [PDF]

				M. G. Manfredi, S. Lim, K. P. Claffey, and T. N. Seyfried Gangliosides Influence Angiogenesis in an Experimental Mouse Brain Tumor Cancer Res., October 1, 1999; 59(20): 5392 - 5397. [Abstract] [Full Text] [PDF]